Kathryn Wheeler, PharmD, BCPS
Kathryn Wheeler, PharmD, BCPS, is assistant clinical professor of pharmacy practice, University of Connecticut School of Pharmacy, Storrs, Conn.
Sugammadex: The First Selective Relaxant Binding Agent
Sugammadex reverses vecuronium and rocuronium, two drugs used to facilitate endotracheal intubation in surgery.
Natpara, a new treatment for hypoparathyroidism
Natpara is indicated only as adjunctive therapy to calcium and vitamin D supplementation and is available only through a restricted REMS program.
MTM essentials for COPD management : Part 2, July 2015 CPE
MTM essentials for COPD management : Part 2, July 2015 CPE
Pharmacists' oversight, counseling, and education of patients with COPD can reduce hospitalizations, improve outcomes, and ward off expensive CMS penalties. Everybody wins.
MTM essentials for COPD management: Part 1
MTM essentials for COPD management: Part 1
Proper pharmacologic treatment for COPD can reduce exacerbations and improve symptoms, reducing the burden on patients and healthcare systems. Pharmacist MTM is key.
Breakthrough treatment approved for advanced melanoma
Last December, FDA granted accelerated approval to nivolumab for treatment of unresectable or metastatic melanoma in patients with cancer that no longer responds to other therapies.
FDA approves new antibiotic combo for two complicated infections
Ceftolozane/tazobactam was approved to treat complicated urinary tract infections and to treat — in combination with metronidazole — complicated intra-abdominal infections.
New once-weekly treatment for type 2 DM
Albiglutide injection is the newest GLP-1 approved for once-weekly dosing in patients with type II diabetes, to be used in addition to diet and exercise.
New adjunctive treatment for partial-onset seizures
FDA approved eslicarbazepine acetate on November 8, 2013 as an adjunctive treatment of partial-onset seizures in adults.
First drug of new class available for PAH
Riociguat (Adempas, Bayer Healthcare Pharmaceuticals Inc.) was approved by FDA on October 8, 2013 for two patient groups. It is intended for patients with pulmonary arterial hypertension (PAH) World Health Organization (WHO) group 1 to improve exercise capacity, improve WHO functional class, and delay clinical worsening. It is also approved for patients with pulmonary hypertension (PH) WHO Group IV who have inoperable or persistent/recurrent postoperative chronic thromboembolic pulmonary hypertension (CTEPH), with the intent of improving exercise capacity and WHO functional class.